Conditions and special cases

retatrutide and PCOS

Published May 3, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

Retatrutide is not approved for PCOS. PCOS questions should stay anchored in endocrine and OB-GYN care.

Direct answer

There is no FDA-approved retatrutide indication for PCOS. People with PCOS may be interested because PCOS can involve insulin resistance, weight changes, irregular periods, and metabolic risk, but retatrutide remains investigational and should not be used outside a Lilly clinical trial.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quotegreater weight loss

Lyu et al., 2021 systematic review and meta-analysis of GLP-1 receptor agonists in PCOS

PCOS research on GLP-1 receptor agonists is not retatrutide evidence. It is included only to frame why clinician-led metabolic care matters.

Short source quotesignificantly reduces body weight

Carmina and Longo, Journal of Clinical Medicine 2023 semaglutide in PCOS study

This small PCOS semaglutide study is relevant only as GLP-1 context; it does not establish retatrutide as a PCOS treatment.

Short source quoteObesity is a global health challenge

Wilding et al., NEJM 2021 STEP 1 semaglutide obesity trial

This semaglutide trial provides approved-GLP-1 context for comparison and alternatives pages, not retatrutide dosing guidance.

What to know before acting on this search

ACOG says PCOS may involve insulin resistance, higher androgen levels, and irregular menstrual cycles.
The Endocrine Society notes that insulin resistance is a major risk factor for type 2 diabetes in many women with PCOS.
Retatrutide is being studied for obesity, type 2 diabetes, and several related conditions, but that is not the same as a PCOS approval.
Cycle changes, fertility goals, pregnancy planning, diabetes risk, and other medications make clinician guidance especially important.

Safety and compliance notes

Do not use weight-loss anecdotes to infer PCOS treatment effectiveness.
People who may become pregnant should discuss any incretin-based therapy or weight-loss drug with an OB-GYN or endocrinologist.
Irregular periods, sudden cycle changes, severe symptoms, or fertility concerns deserve medical evaluation.

Safer next step

Use this page as a question list for an OB-GYN, endocrinologist, or obesity-medicine clinician rather than as treatment guidance.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.